LINK . SPRINGER . COM {}

Matching Content Categories {📚}

• Education
• Science
• Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

Not every website is profit-driven; some are created to spread information or serve as an online presence. Websites can be made for many reasons. This could be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

article, pubmed, cancer, google, scholar, cas, ccl, carlumab, phase, research, tumor, chemotherapy, study, combination, patients, solid, tumors, puchalski, seetharam, human, central, chemokine, antibody, gemcitabine, access, clin, res, pienta, janssen, author, privacy, cookies, content, oncology, ligand, regimens, treatment, calles, docetaxel, cells, trial, chemoattractant, protein, prostate, snyder, usa, data, publish, search, monoclonal,

Topics {✒️}

/clinical-cancer-research-abstracts/complete-phase-ib-trial-design ras/raf/mek/erk/nf-κb signaling pathway month download article/chapter ccl2-ccr2a/2b signaling advanced solid tumors cc chemokine mcp-1/ccl2 dose-limiting toxicities included phase ii faster phase ib study line therapy outcomes breast cancer-derived fibroblasts chemokine ccl2 gene full article pdf author correspondence cc-chemokine ligand 2 human monoclonal antibody solid tumors daniel von hoff prostate cancer aggressiveness clinical trials conducting research sponsored privacy choices/manage cookies carboplatin therapy macrophage chemoattractant protein-1 article brana check access instant access combination treatment wayne state university carlumab-ccl2 binding treatment options existed human chondrosarcoma cells human nk cells circulating endothelial cells paclitaxel + carboplatin arm—neutropenia ccl2-dependent recruitment human breast cancer t-lymphocyte chemoattractant circulating tumor cells monocyte-chemotactic proteins cancer research 72 related subjects serum ccl2 phase 2 study human melanoma xenograft chemokine ligand 2 stimulates tumor growth european economic area stable disease responses long-term suppression

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
         description:C-C chemokine ligand 2 (CCL2) stimulates tumor growth, metastasis, and angiogenesis. Carlumab, a human IgG1κ anti-CCL2 mAb, has shown antitumor activity in preclinical and clinical trials. We conducted a first-in-human phase 1b study of carlumab with one of four chemotherapy regimens (docetaxel, gemcitabine, paclitaxel + carboplatin, and pegylated liposomal doxorubicin HCl [PLD]). Patients had advanced solid tumors for which ≥1 of these regimens was considered standard of care or for whom no other treatment options existed. Dose-limiting toxicities included one grade 4 febrile neutropenia (docetaxel arm) and one grade 3 neutropenia (gemcitabine arm). Combination treatment with carlumab had no clinically relevant pharmacokinetic effect on docetaxel (n = 15), gemcitabine (n = 12), paclitaxel or carboplatin (n = 12), or PLD (n = 14). Total serum CCL2 concentrations increased post-treatment with carlumab alone, consistent with carlumab-CCL2 binding, and continued increase in the presence of all chemotherapy regimens. Free CCL2 declined immediately post-treatment with carlumab but increased with further chemotherapy administrations in all arms, suggesting that carlumab could sequester CCL2 for only a short time. Neither antibodies against carlumab nor consistent changes in circulating tumor cells (CTCs) or circulating endothelial cells (CECs) enumeration were observed. Three of 19 evaluable patients showed a 30 % decrease from baseline urinary cross-linked N-telopeptide of type I collagen (uNTx). One partial response and 18 (38 %) stable disease responses were observed. The most common drug-related grade ≥3 adverse events were docetaxel arm—neutropenia (6/15) and febrile neutropenia (4/15); gemcitabine arm—neutropenia (2/12); paclitaxel + carboplatin arm—neutropenia, thrombocytopenia (4/12 each), and anemia (2/12); and PLD arm—anemia (3/14) and stomatitis (2/14). Carlumab could be safely administered at 10 or 15 mg/kg in combination with standard-of-care chemotherapy and was well-tolerated, although no long-term suppression of serum CCL2 or significant tumor responses were observed.
         datePublished:2014-06-15T00:00:00Z
         dateModified:2014-06-15T00:00:00Z
         pageStart:111
         pageEnd:123
         sameAs:https://doi.org/10.1007/s11523-014-0320-2
         keywords:
            Carlumab
            Chemokine CCL2
            Combination chemotherapy
            Clinical trial
            Phase 1
            Solid tumors
            Oncology
            Biomedicine
            general
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-014-0320-2/MediaObjects/11523_2014_320_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-014-0320-2/MediaObjects/11523_2014_320_Fig2_HTML.gif
         isPartOf:
            name:Targeted Oncology
            issn:
               1776-260X
               1776-2596
            volumeNumber:10
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Irene Brana
               affiliation:
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Antonio Calles
               affiliation:
                     name:Centro Integral Oncológico Clara Campal
                     address:
                        name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
                        type:PostalAddress
                     type:Organization
                     name:Spanish National Cancer Research Centre (CNIO)
                     address:
                        name:Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Patricia M. LoRusso
               affiliation:
                     name:Wayne State University
                     address:
                        name:Karmanos Cancer Institute, Wayne State University, Detroit, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lorrin K. Yee
               affiliation:
                     name:Northwest Medical Specialties
                     address:
                        name:Northwest Medical Specialties, Tacoma, USA
                        type:PostalAddress
                     type:Organization
                     name:Vista Oncology
                     address:
                        name:Vista Oncology, Olympia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas A. Puchalski
               affiliation:
                     name:Janssen Research & Development, LLC
                     address:
                        name:Janssen Research & Development, LLC, Spring House, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Shobha Seetharam
               affiliation:
                     name:Janssen Research & Development, LLC
                     address:
                        name:Janssen Research & Development, LLC, Spring House, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bob Zhong
               affiliation:
                     name:Janssen Research & Development, LLC
                     address:
                        name:Janssen Research & Development, LLC, Spring House, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Carla J. de Boer
               affiliation:
                     name:Janssen Biologics, BV
                     address:
                        name:Janssen Biologics, BV, Leiden, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Josep Tabernero
               affiliation:
                     name:Universitat Autònoma de Barcelona
                     address:
                        name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Emiliano Calvo
               affiliation:
                     name:Centro Integral Oncológico Clara Campal
                     address:
                        name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
      description:C-C chemokine ligand 2 (CCL2) stimulates tumor growth, metastasis, and angiogenesis. Carlumab, a human IgG1κ anti-CCL2 mAb, has shown antitumor activity in preclinical and clinical trials. We conducted a first-in-human phase 1b study of carlumab with one of four chemotherapy regimens (docetaxel, gemcitabine, paclitaxel + carboplatin, and pegylated liposomal doxorubicin HCl [PLD]). Patients had advanced solid tumors for which ≥1 of these regimens was considered standard of care or for whom no other treatment options existed. Dose-limiting toxicities included one grade 4 febrile neutropenia (docetaxel arm) and one grade 3 neutropenia (gemcitabine arm). Combination treatment with carlumab had no clinically relevant pharmacokinetic effect on docetaxel (n = 15), gemcitabine (n = 12), paclitaxel or carboplatin (n = 12), or PLD (n = 14). Total serum CCL2 concentrations increased post-treatment with carlumab alone, consistent with carlumab-CCL2 binding, and continued increase in the presence of all chemotherapy regimens. Free CCL2 declined immediately post-treatment with carlumab but increased with further chemotherapy administrations in all arms, suggesting that carlumab could sequester CCL2 for only a short time. Neither antibodies against carlumab nor consistent changes in circulating tumor cells (CTCs) or circulating endothelial cells (CECs) enumeration were observed. Three of 19 evaluable patients showed a 30 % decrease from baseline urinary cross-linked N-telopeptide of type I collagen (uNTx). One partial response and 18 (38 %) stable disease responses were observed. The most common drug-related grade ≥3 adverse events were docetaxel arm—neutropenia (6/15) and febrile neutropenia (4/15); gemcitabine arm—neutropenia (2/12); paclitaxel + carboplatin arm—neutropenia, thrombocytopenia (4/12 each), and anemia (2/12); and PLD arm—anemia (3/14) and stomatitis (2/14). Carlumab could be safely administered at 10 or 15 mg/kg in combination with standard-of-care chemotherapy and was well-tolerated, although no long-term suppression of serum CCL2 or significant tumor responses were observed.
      datePublished:2014-06-15T00:00:00Z
      dateModified:2014-06-15T00:00:00Z
      pageStart:111
      pageEnd:123
      sameAs:https://doi.org/10.1007/s11523-014-0320-2
      keywords:
         Carlumab
         Chemokine CCL2
         Combination chemotherapy
         Clinical trial
         Phase 1
         Solid tumors
         Oncology
         Biomedicine
         general
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-014-0320-2/MediaObjects/11523_2014_320_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11523-014-0320-2/MediaObjects/11523_2014_320_Fig2_HTML.gif
      isPartOf:
         name:Targeted Oncology
         issn:
            1776-260X
            1776-2596
         volumeNumber:10
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Irene Brana
            affiliation:
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Antonio Calles
            affiliation:
                  name:Centro Integral Oncológico Clara Campal
                  address:
                     name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
                     type:PostalAddress
                  type:Organization
                  name:Spanish National Cancer Research Centre (CNIO)
                  address:
                     name:Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Patricia M. LoRusso
            affiliation:
                  name:Wayne State University
                  address:
                     name:Karmanos Cancer Institute, Wayne State University, Detroit, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lorrin K. Yee
            affiliation:
                  name:Northwest Medical Specialties
                  address:
                     name:Northwest Medical Specialties, Tacoma, USA
                     type:PostalAddress
                  type:Organization
                  name:Vista Oncology
                  address:
                     name:Vista Oncology, Olympia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas A. Puchalski
            affiliation:
                  name:Janssen Research & Development, LLC
                  address:
                     name:Janssen Research & Development, LLC, Spring House, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Shobha Seetharam
            affiliation:
                  name:Janssen Research & Development, LLC
                  address:
                     name:Janssen Research & Development, LLC, Spring House, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bob Zhong
            affiliation:
                  name:Janssen Research & Development, LLC
                  address:
                     name:Janssen Research & Development, LLC, Spring House, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Carla J. de Boer
            affiliation:
                  name:Janssen Biologics, BV
                  address:
                     name:Janssen Biologics, BV, Leiden, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Josep Tabernero
            affiliation:
                  name:Universitat Autònoma de Barcelona
                  address:
                     name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Emiliano Calvo
            affiliation:
                  name:Centro Integral Oncológico Clara Campal
                  address:
                     name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Targeted Oncology
      issn:
         1776-260X
         1776-2596
      volumeNumber:10
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Universitat Autònoma de Barcelona
      address:
         name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
         type:PostalAddress
      name:Centro Integral Oncológico Clara Campal
      address:
         name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
         type:PostalAddress
      name:Spanish National Cancer Research Centre (CNIO)
      address:
         name:Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
         type:PostalAddress
      name:Wayne State University
      address:
         name:Karmanos Cancer Institute, Wayne State University, Detroit, USA
         type:PostalAddress
      name:Northwest Medical Specialties
      address:
         name:Northwest Medical Specialties, Tacoma, USA
         type:PostalAddress
      name:Vista Oncology
      address:
         name:Vista Oncology, Olympia, USA
         type:PostalAddress
      name:Janssen Research & Development, LLC
      address:
         name:Janssen Research & Development, LLC, Spring House, USA
         type:PostalAddress
      name:Janssen Research & Development, LLC
      address:
         name:Janssen Research & Development, LLC, Spring House, USA
         type:PostalAddress
      name:Janssen Research & Development, LLC
      address:
         name:Janssen Research & Development, LLC, Spring House, USA
         type:PostalAddress
      name:Janssen Biologics, BV
      address:
         name:Janssen Biologics, BV, Leiden, The Netherlands
         type:PostalAddress
      name:Universitat Autònoma de Barcelona
      address:
         name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
         type:PostalAddress
      name:Centro Integral Oncológico Clara Campal
      address:
         name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Irene Brana
      affiliation:
            name:Universitat Autònoma de Barcelona
            address:
               name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:Antonio Calles
      affiliation:
            name:Centro Integral Oncológico Clara Campal
            address:
               name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
               type:PostalAddress
            type:Organization
            name:Spanish National Cancer Research Centre (CNIO)
            address:
               name:Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Patricia M. LoRusso
      affiliation:
            name:Wayne State University
            address:
               name:Karmanos Cancer Institute, Wayne State University, Detroit, USA
               type:PostalAddress
            type:Organization
      name:Lorrin K. Yee
      affiliation:
            name:Northwest Medical Specialties
            address:
               name:Northwest Medical Specialties, Tacoma, USA
               type:PostalAddress
            type:Organization
            name:Vista Oncology
            address:
               name:Vista Oncology, Olympia, USA
               type:PostalAddress
            type:Organization
      name:Thomas A. Puchalski
      affiliation:
            name:Janssen Research & Development, LLC
            address:
               name:Janssen Research & Development, LLC, Spring House, USA
               type:PostalAddress
            type:Organization
      name:Shobha Seetharam
      affiliation:
            name:Janssen Research & Development, LLC
            address:
               name:Janssen Research & Development, LLC, Spring House, USA
               type:PostalAddress
            type:Organization
      name:Bob Zhong
      affiliation:
            name:Janssen Research & Development, LLC
            address:
               name:Janssen Research & Development, LLC, Spring House, USA
               type:PostalAddress
            type:Organization
      name:Carla J. de Boer
      affiliation:
            name:Janssen Biologics, BV
            address:
               name:Janssen Biologics, BV, Leiden, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Josep Tabernero
      affiliation:
            name:Universitat Autònoma de Barcelona
            address:
               name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
               type:PostalAddress
            type:Organization
      name:Emiliano Calvo
      affiliation:
            name:Centro Integral Oncológico Clara Campal
            address:
               name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
      name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
      name:Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
      name:Karmanos Cancer Institute, Wayne State University, Detroit, USA
      name:Northwest Medical Specialties, Tacoma, USA
      name:Vista Oncology, Olympia, USA
      name:Janssen Research & Development, LLC, Spring House, USA
      name:Janssen Research & Development, LLC, Spring House, USA
      name:Janssen Research & Development, LLC, Spring House, USA
      name:Janssen Biologics, BV, Leiden, The Netherlands
      name:Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain
      name:START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(140)

• What are the total earnings of https://www.springernature.com/gp/authors?
• How much does https://link.springernature.com/home/ gross monthly?
• Learn how profitable https://order.springer.com/public/cart is on a monthly basis
• How much income does https://www.editorialmanager.com/targ have?
• How much does https://www.springernature.com/gp/librarians/licensing/agc/journals gross monthly?
• Learn how profitable https://doi.org/10.1182/blood-2011-08-370908 is on a monthly basis
• Explore the financials of https://doi.org/10.1182%2Fblood-2011-08-370908
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22289889
• Profit of http://scholar.google.com/scholar_lookup?&title=Mesenchymal%20stromal%20cells%20orchestrate%20follicular%20lymphoma%20cell%20niche%20through%20the%20CCL2-dependent%20recruitment%20and%20polarization%20of%20monocytes&journal=Blood&doi=10.1182%2Fblood-2011-08-370908&volume=119&pages=2556-2567&publication_year=2012&author=Guilloton%2CF&author=Caron%2CG&author=M%C3%A9nard%2CC&author=Pangault%2CC&author=Am%C3%A9-Thomas%2CP&author=Dulong%2CJ&author=Vos%2CJ&author=Rossille%2CD&author=Henry%2CC&author=Lamy%2CT&author=Fouquet%2CO&author=Fest%2CT&author=Tarte%2CK
• What's https://doi.org/10.1073%2Fpnas.91.9.3652's gross income?
• What's the revenue for http://www.ncbi.nlm.nih.gov/pmc/articles/PMC43639?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=8170963 net monthly?
• Find out how much http://scholar.google.com/scholar_lookup?&title=Monocyte%20chemoattractant%20protein%201%20acts%20as%20a%20T-lymphocyte%20chemoattractant&journal=Proc%20Natl%20Acad%20Sci%20U%20S%20A&doi=10.1073%2Fpnas.91.9.3652&volume=91&pages=3652-3656&publication_year=1994&author=Carr%2CMW&author=Roth%2CSJ&author=Luther%2CE&author=Rose%2CSS&author=Springer%2CTA earns monthly
• What's the financial outcome of https://doi.org/10.1016/S0002-9440(10)62289-4?
• How much income does https://doi.org/10.1016%2FS0002-9440%2810%2962289-4 have?
• What's the income generated by http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1780139 each month?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=15743780 net monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=CCR2-mediated%20recruitment%20of%20fibrocytes%20to%20the%20alveolar%20space%20after%20fibrotic%20injury&journal=Am%20J%20Pathol&doi=10.1016%2FS0002-9440%2810%2962289-4&volume=166&pages=675-684&publication_year=2005&author=Moore%2CBB&author=Kolodsick%2CJE&author=Thannickal%2CVJ&author=Cooke%2CK&author=Moore%2CTA&author=Hogaboam%2CC&author=Wilke%2CCA&author=Toews%2CGB bring in each month?
• What's the total monthly financial gain of https://doi.org/10.3747/pdi.2010.00200?
• Financial intake of https://doi.org/10.3747%2Fpdi.2010.00200
• How much revenue does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525367 bring in?
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21719683?
• http://scholar.google.com/scholar_lookup?&title=Activation%20of%20p38%20mitogen-activated%20protein%20kinase%20promotes%20peritoneal%20fibrosis%20by%20regulating%20fibrocytes&journal=Perit%20Dial%20Int&doi=10.3747%2Fpdi.2010.00200&volume=32&pages=10-19&publication_year=2012&author=Kokubo%2CS&author=Sakai%2CN&author=Furuichi%2CK&author=Toyama%2CT&author=Kitajima%2CS&author=Okumura%2CT&author=Matsushima%2CK&author=Kaneko%2CS&author=Wada%2CT's revenue stream
• How much cash flow does https://doi.org/10.1016/j.bcp.2011.11.013 have monthly?
• How much does https://doi.org/10.1016%2Fj.bcp.2011.11.013 earn?
• http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22138288's revenue stream
• How much does http://scholar.google.com/scholar_lookup?&title=CCL2%20increases%20MMP-9%20expression%20and%20cell%20motility%20in%20human%20chondrosarcoma%20cells%20via%20the%20Ras%2FRaf%2FMEK%2FERK%2FNF-%CE%BAB%20signaling%20pathway&journal=Biochem%20Pharmacol&doi=10.1016%2Fj.bcp.2011.11.013&volume=83&pages=335-344&publication_year=2012&author=Tang%2CC-H&author=Tsai%2CC-C bring in each month?
• What's https://doi.org/10.1006/meth.1996.0088's gross income?
• See how much https://doi.org/10.1016/j.imbio.2010.05.019 makes per month
• How much does https://doi.org/10.1016%2Fj.imbio.2010.05.019 generate monthly?
• Check the income stats for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=20605053
• What's the financial gain of http://scholar.google.com/scholar_lookup?&title=Importance%20of%20CCL2-CCR2A%2F2B%20signaling%20for%20monocyte%20migration%20into%20spheroids%20of%20breast%20cancer-derived%20fibroblasts&journal=Immunobiology&doi=10.1016%2Fj.imbio.2010.05.019&volume=215&pages=737-747&publication_year=2010&author=Ksiazkiewicz%2CM&author=Gottfried%2CE&author=Kreutz%2CM&author=Mack%2CM&author=Hofstaedter%2CF&author=Kunz-Schughart%2CLA?
• How much does https://doi.org/10.4049/jimmunol.180.4.2011 generate monthly?
• How much cash flow does https://doi.org/10.1371/journal.pone.0040058 have monthly?
• Get to know what's the income of https://doi.org/10.1371%2Fjournal.pone.0040058
• http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391227's revenue stream
• Profit of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22792213
• How much does http://scholar.google.com/scholar_lookup?&title=Integrating%20macrophages%20into%20organotypic%20co-cultures%3A%20a%203D%20in%20vitro%20model%20to%20study%20tumor-associated%20macrophages&journal=PLoS%20ONE&doi=10.1371%2Fjournal.pone.0040058&volume=7&publication_year=2012&author=Linde%2CN&author=Gutschalk%2CCM&author=Hoffmann%2CC&author=Yilmaz%2CD&author=Mueller%2CMM generate monthly?
• What's the income generated by https://doi.org/10.1155/2012/948098 each month?
• How much does https://doi.org/10.1155%2F2012%2F948098 pull in monthly?
• How much does http://scholar.google.com/scholar_lookup?&title=Macrophages%20in%20tumor%20microenvironments%20and%20the%20progression%20of%20tumors&journal=Clin%20Dev%20Immunol&doi=10.1155%2F2012%2F948098&volume=2012&pages=1-11&publication_year=2012&author=Hao%2CN-B&author=L%C3%BC%2CM-H&author=Fan%2CY-H&author=Cao%2CY-L&author=Zhang%2CZ-R&author=Yang%2CS-M bring in each month?
• How much income does https://doi.org/10.1002/1097-0142(20010901)92:5%3C1085::AID-CNCR1424%3E3.0.CO;2-K have?
• What are the total earnings of https://doi.org/10.1002%2F1097-0142%2820010901%2992%3A5%3C1085%3A%3AAID-CNCR1424%3E3.0.CO%3B2-K?
• Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=11571719 earns monthly
• What's the profit of http://scholar.google.com/scholar_lookup?&title=Significant%20correlation%20of%20monocyte%20chemoattractant%20protein-1%20expression%20with%20neovascularization%20and%20progression%20of%20breast%20carcinoma&journal=Cancer&doi=10.1002%2F1097-0142%2820010901%2992%3A5%3C1085%3A%3AAID-CNCR1424%3E3.0.CO%3B2-K&volume=92&pages=1085-1091&publication_year=2001&author=Saji%2CH&author=Koike%2CM&author=Yamori%2CT&author=Saji%2CS&author=Seiki%2CM&author=Matsushima%2CK&author=Toi%2CM?
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=10955814 bring in?
• How much profit does http://scholar.google.com/scholar_lookup?&title=Significance%20of%20macrophage%20chemoattractant%20protein-1%20in%20macrophage%20recruitment%2C%20angiogenesis%2C%20and%20survival%20in%20human%20breast%20cancer&journal=Clin%20Cancer%20Res&volume=6&pages=3282-3289&publication_year=2000&author=Ueno%2CT&author=Toi%2CM&author=Saji%2CH&author=Muta%2CM&author=Bando%2CH&author=Kuroi%2CK&author=Koike%2CM&author=Inadera%2CH&author=Matsushima%2CK generate?
• How much does https://doi.org/10.1158/1078-0432.CCR-10-2015 gross monthly?
• Revenue of https://doi.org/10.1158%2F1078-0432.CCR-10-2015
• How much money does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3060307 make?
• How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=21135144?
• How profitable is http://scholar.google.com/scholar_lookup?&title=Inherited%20variants%20in%20the%20chemokine%20CCL2%20gene%20and%20prostate%20cancer%20aggressiveness%20in%20a%20Caucasian%20cohort&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-10-2015&volume=17&pages=1546-1552&publication_year=2011&author=Sun%2CT&author=Lee%2CG-SM&author=Oh%2CWK&author=Freedman%2CML&author=Pomerantz%2CM&author=Pienta%2CKJ&author=Kantoff%2CPW?
• How much profit does https://doi.org/10.1007/s10456-011-9244-y generate?
• What is the monthly revenue of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22210436?
• How much does http://scholar.google.com/scholar_lookup?&title=Down-modulation%20of%20TNFSF15%20in%20ovarian%20cancer%20by%20VEGF%20and%20MCP-1%20is%20a%20pre-requisite%20for%20tumor%20neovascularization&journal=Angiogenesis&doi=10.1007%2Fs10456-011-9244-y&volume=15&pages=71-85&publication_year=2012&author=Deng%2CW&author=Gu%2CX&author=Lu%2CY&author=Gu%2CC&author=Zheng%2CY&author=Zhang%2CZ&author=Chen%2CL&author=Yao%2CZ&author=Li%2CL-Y gross monthly?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=14612545
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=The%20CC%20chemokine%20MCP-1%2FCCL2%20in%20pancreatic%20cancer%20progression%3A%20regulation%20of%20expression%20and%20potential%20mechanisms%20of%20antimalignant%20activity&journal=Cancer%20Res&volume=63&pages=7451-7461&publication_year=2003&author=Monti%2CP&author=Leone%2CBE&author=Marchesi%2CF&author=Balzano%2CG&author=Zerbi%2CA&author=Scaltrini%2CF&author=Pasquali%2CC&author=Calori%2CG&author=Pessi%2CF&author=Sperti%2CC&author=Carlo%2CV&author=Allavena%2CP&author=Piemonti%2CL
• How much does https://doi.org/10.1593/neo.06280 pull in monthly?
• Revenue of https://doi.org/10.1158/0008-5472.CAN-08-2164
• https://doi.org/10.1158%2F0008-5472.CAN-08-2164's financial summary
• How much cash flow does http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2698812 have monthly?
• Get to know what's the income of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19176388
• How much does http://scholar.google.com/scholar_lookup?&title=A%20destructive%20cascade%20mediated%20by%20CCL2%20facilitates%20prostate%20cancer%20growth%20in%20bone&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-08-2164&volume=69&pages=1685-1692&publication_year=2009&author=Li%2CX&author=Loberg%2CR&author=Liao%2CJ&author=Ying%2CC&author=Snyder%2CLA&author=Pienta%2CKJ&author=McCauley%2CLK gross monthly?
• Profit of https://doi.org/10.1159/000077718
• How much does https://doi.org/10.1159%2F000077718 pull in?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Monocyte%20chemoattractant%20protein-1%20serum%20levels%20in%20patients%20with%20breast%20cancer&journal=Tumor%20Biol&doi=10.1159%2F000077718&volume=25&pages=14-17&publication_year=2004&author=Lebrecht%2CA&author=Grimm%2CC&author=Lantzsch%2CT&author=Ludwig%2CE&author=Hefler%2CL&author=Ulbrich%2CE&author=Koelbl%2CH
• What's the financial outcome of https://doi.org/10.1158/0008-5472.CAN-07-1286?
• How much does https://doi.org/10.1158%2F0008-5472.CAN-07-1286 generate monthly?
• How profitable is http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17909051?
• How much does http://scholar.google.com/scholar_lookup?&title=Targeting%20CCL2%20with%20systemic%20delivery%20of%20neutralizing%20antibodies%20induces%20prostate%20cancer%20tumor%20regression%20in%20vivo&journal=Cancer%20Res&doi=10.1158%2F0008-5472.CAN-07-1286&volume=67&pages=9417-9424&publication_year=2007&author=Loberg%2CRD&author=Ying%2CC&author=Craig%2CM&author=Day%2CLL&author=Sargent%2CE&author=Neeley%2CC&author=Wojno%2CK&author=Snyder%2CLA&author=Yan%2CL&author=Pienta%2CKJ pull in?
• How much revenue does https://doi.org/10.1038/sj.jid.5700827 produce monthly?
• What's the monthly income of https://doi.org/10.1038%2Fsj.jid.5700827?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=17460736 generate monthly?
• What's the financial intake of http://scholar.google.com/scholar_lookup?&title=Targeting%20tumor-associated%20macrophages%20and%20inhibition%20of%20MCP-1%20reduce%20angiogenesis%20and%20tumor%20growth%20in%20a%20human%20melanoma%20xenograft&journal=J%20Investig%20Dermatol&doi=10.1038%2Fsj.jid.5700827&volume=127&pages=2031-2041&publication_year=2007&author=Gazzaniga%2CS&author=Bravo%2CAI&author=Guglielmotti%2CA&author=Rooijen%2CN&author=Maschi%2CF&author=Vecchi%2CA&author=Mantovani%2CA&author=Mordoh%2CJ&author=Wainstok%2CR?
• Learn how profitable https://doi.org/10.1007/s00280-013-2099-8 is on a monthly basis
• How much revenue does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=23385782 bring in?
• How much does http://scholar.google.com/scholar_lookup?&title=A%20first-in-human%2C%20first-in-class%2C%20phase%20I%20study%20of%20carlumab%20%28CNTO%20888%29%2C%20a%20human%20monoclonal%20antibody%20against%20CC-chemokine%20ligand%202%20in%20patients%20with%20solid%20tumors&journal=Cancer%20Chemother%20Pharmacol&doi=10.1007%2Fs00280-013-2099-8&volume=71&pages=1041-1050&publication_year=2013&author=Sandhu%2CSK&author=Papadopoulos%2CK&author=Fong%2CPC&author=Patnaik%2CA&author=Messiou%2CC&author=Olmos%2CD&author=Wang%2CG&author=Tromp%2CBJ&author=Puchalski%2CTA&author=Balkwill%2CF&author=Berns%2CB&author=Seetharam%2CS&author=Bono%2CJS&author=Tolcher%2CAW pull in?
• What's the profit of https://doi.org/10.1016/j.molimm.2012.03.022?
• Profit of https://doi.org/10.1016%2Fj.molimm.2012.03.022
• What's the financial gain of http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22487721?
• Earnings of http://scholar.google.com/scholar_lookup?&title=Structural%20basis%20for%20high%20selectivity%20of%20anti-CCL2%20neutralizing%20antibody%20CNTO%20888&journal=Mol%20Immunol&doi=10.1016%2Fj.molimm.2012.03.022&volume=51&pages=227-233&publication_year=2012&author=Obmolova%2CG&author=Teplyakov%2CA&author=Malia%2CTJ&author=Grygiel%2CTLR&author=Sweet%2CR&author=Snyder%2CLA&author=Gilliland%2CGL
• What are the total earnings of https://doi.org/10.1002/jcb.22056?
• What's the profit of https://doi.org/10.1002%2Fjcb.22056?
• What's the profit of http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293017?
• Find out how much http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=19259948 earns monthly
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=Synergy%20between%20anti-CCL2%20and%20docetaxel%20as%20determined%20by%20DW-MRI%20in%20a%20metastatic%20bone%20cancer%20model&journal=J%20Cell%20Biochem&doi=10.1002%2Fjcb.22056&volume=107&pages=58-64&publication_year=2009&author=Rozel%2CS&author=Galb%C3%A1n%2CCJ&author=Nicolay%2CK&author=Lee%2CKC&author=Sud%2CS&author=Neeley%2CC&author=Snyder%2CLA&author=Chenevert%2CTL&author=Rehemtulla%2CA&author=Ross%2CBD&author=Pienta%2CKJ
• What's https://doi.org/10.1007/s10637-012-9869-8's gross income?
• How much does http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=22907596 rake in every month?
• What is the earnings of http://scholar.google.com/scholar_lookup?&title=Phase%202%20study%20of%20carlumab%20%28CNTO%20888%29%2C%20a%20human%20monoclonal%20antibody%20against%20CC-chemokine%20ligand%202%20%28CCL2%29%2C%20in%20metastatic%20castration-resistant%20prostate%20cancer&journal=Invest%20New%20Drugs&doi=10.1007%2Fs10637-012-9869-8&volume=31&pages=760-768&publication_year=2013&author=Pienta%2CKJ&author=Machiels%2CJ-P&author=Schrijvers%2CD&author=Alekseev%2CB&author=Shkolnik%2CM&author=Crabb%2CSJ&author=Li%2CS&author=Seetharam%2CS&author=Puchalski%2CTA&author=Takimoto%2CC&author=Elsayed%2CY&author=Dawkins%2CF&author=Bono%2CJS?
• How much profit is http://scholar.google.com/scholar_lookup?&title=Pharmacokinetics%20and%20pharmacodynamics&pages=360-368&publication_year=2011&author=Takimoto%2CCH&author=Ng%2CCM&author=Puchalski%2CT making per month?
• What are the total earnings of https://doi.org/10.1016/j.ejca.2008.10.026?
• What's https://doi.org/10.1158/1078-0432.CCR-07-4885's gross income?
• Explore the financials of https://doi.org/10.1158%2F1078-0432.CCR-07-4885
• What's the monthly money flow for http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=18519786?
• How much revenue does http://scholar.google.com/scholar_lookup?&title=Modulation%20of%20gemcitabine%20%282%E2%80%B2%2C2%E2%80%B2-difluoro-2%E2%80%B2-deoxycytidine%29%20pharmacokinetics%2C%20metabolism%2C%20and%20bioavailability%20in%20mice%20by%203%2C4%2C5%2C6-tetrahydrouridine&journal=Clin%20Cancer%20Res&doi=10.1158%2F1078-0432.CCR-07-4885&volume=14&pages=3529-3535&publication_year=2008&author=Beumer%2CJH&author=Eiseman%2CJL&author=Parise%2CRA&author=Joseph%2CE&author=Covey%2CJM&author=Egorin%2CMJ generate?
• Check the income stats for http://scholar.google.com/scholar_lookup?&title=Utilizing%20mechanistic%20PK%2FPD%20modeling%20to%20simultaneously%20examine%20free%20CCL2%2C%20total%20CCL2%2C%20and%20CNTO%20888%20serum%20concentration%20time%20data%20%5BASCO%20abstract%203029%5D&journal=J%20Clin%20Oncol&volume=28&publication_year=2010&author=Fetterly%2CGJ&author=Puchalski%2CTA&author=Takimoto%2CC&author=Mager%2CDE&author=Seetharam%2CS&author=McIntosh%2CT&author=Bono%2CJS&author=Tolcher%2CA&author=Davis%2CHM&author=Zhou%2CH
• How much income does http://scholar.google.com/scholar_lookup?&title=The%20complete%20phase%20Ib%20clinical%20trial%3A%20a%20method%20to%20accelerate%20new%20agent%20development%20%5BASCO%20abstract%202562%5D&journal=J%20Clin%20Oncol&volume=25&publication_year=2007&author=Hoff%2CDD&author=Nieves%2CJA&author=Vocila%2CLK&author=Weitman%2CSD&author=Cvitkovic%2CE have?
• How much revenue does http://www.medelis.com/clinical-cancer-research-abstracts/complete-phase-ib-trial-design bring in?
• How much revenue does https://citation-needed.springer.com/v2/references/10.1007/s11523-014-0320-2?format=refman&flavour=references bring in?
• How much profit does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Irene%20Brana generate?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Irene%20Brana%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's revenue stream
• What's https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Antonio%20Calles's gross income?
• How much cash flow does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Antonio%20Calles%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have monthly?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Patricia%20M.%20LoRusso bring in each month?
• Revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Patricia%20M.%20LoRusso%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lorrin%20K.%20Yee income
• What's the monthly income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lorrin%20K.%20Yee%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• See how much https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Thomas%20A.%20Puchalski makes per month
• Income figures for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Thomas%20A.%20Puchalski%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the financial outcome of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Shobha%20Seetharam?
• Monthly income for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Shobha%20Seetharam%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the financial intake of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Bob%20Zhong?
• Earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Bob%20Zhong%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• Get to know what's the income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Carla%20J.%20de%20Boer
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Carla%20J.%20de%20Boer%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en pull in monthly?
• Profit of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Josep%20Tabernero
• What's the income of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Josep%20Tabernero%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• Discover the revenue of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Emiliano%20Calvo
• What are the earnings of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Emiliano%20Calvo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the monthly income of https://static-content.springer.com/esm/art%3A10.1007%2Fs11523-014-0320-2/MediaObjects/11523_2014_320_MOESM1_ESM.doc?
• How much does https://static-content.springer.com/esm/art%3A10.1007%2Fs11523-014-0320-2/MediaObjects/11523_2014_320_MOESM2_ESM.eps bring in each month?
• What's the monthly money flow for https://s100.copyright.com/AppDispatchServlet?title=Carlumab%2C%20an%20anti-C-C%20chemokine%20ligand%202%20monoclonal%20antibody%2C%20in%20combination%20with%20four%20chemotherapy%20regimens%20for%20the%20treatment%20of%20patients%20with%20solid%20tumors%3A%20an%20open-label%2C%20multicenter%20phase%201b%20study&author=Irene%20Brana%20et%20al&contentID=10.1007%2Fs11523-014-0320-2©right=Springer%20International%20Publishing%20Switzerland&publication=1776-2596&publicationDate=2014-06-15&publisherName=SpringerNature&orderBeanReset=true?
• See how much https://crossmark.crossref.org/dialog/?doi=10.1007/s11523-014-0320-2 makes per month
• https://citation-needed.springer.com/v2/references/10.1007/s11523-014-0320-2?format=refman&flavour=citation's total income per month
• What are the earnings of https://authorservices.springernature.com/go/sn/?utm_source=SNLinkfooter&utm_medium=Web&utm_campaign=SNReferral?
• Profit of https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research
• https://www.springernature.com/gp/products's revenue stream
• How much does https://www.springernature.com/gp/librarians rake in every month?
• Discover the revenue of https://www.springernature.com/gp/societies
• Learn how profitable https://www.springernature.com/gp/partners is on a monthly basis
• See how much https://www.springer.com/ makes per month
• https://www.nature.com/'s revenue stream
• Learn about the earnings of https://www.biomedcentral.com/
• How much money does https://www.palgrave.com/ make?
• How much profit does https://www.apress.com/ make?
• What's the financial gain of https://www.springernature.com/gp/legal/ccpa?
• How much does https://www.springernature.com/gp/info/accessibility make?
• How much money does https://support.springernature.com/en/support/home generate?
• Check the income stats for https://support.springernature.com/en/support/solutions/articles/6000255911-subscription-cancellations
• https://www.springernature.com/'s financial summary

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Clipboard.js
• Prism.js

CDN Services {📦}

• Crossref